Escitalopram in the treatment of obsessive-compulsive disorder

Research output: Contribution to journalReview articlepeer-review

Abstract

Obsessive-compulsive disorder (OCD) is a chronic, distressing illness that is associated with a specific and unique response to selective serotonin reuptake inhibitors. Escitalopram was granted marketing authorization for the treatment of OCD from the European authorities in 2007 based on results from two Phase-III clinical trials in patients with moderate-to-severe OCD. One, a relapse prevention study, demonstrated substantial efficacy of escitalopram 10-20 mg/day in both acute and maintenance treatment, and the other demonstrated superior efficacy and favorable tolerability of escitalopram compared with placebo during 24-week, double-blind treatment. These data, and other studies reviewed here, suggest that escitalopram is an important additional tool for the treatment of OCD.

Original languageEnglish
Pages (from-to)339-349
Number of pages11
JournalExpert Review of Neurotherapeutics
Volume8
Issue number3
DOIs
StatePublished - Mar 2008
Externally publishedYes

Keywords

  • Escitalopram
  • Maintenance treatment
  • Obsessive-compulsive disorder
  • Relapse prevention
  • Selective serotonin reuptake inhibitor
  • Serotonin

Fingerprint

Dive into the research topics of 'Escitalopram in the treatment of obsessive-compulsive disorder'. Together they form a unique fingerprint.

Cite this